

**Remarks/Arguments** begin on page 5 of this paper.

**I. AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for the ~~prevention of~~inhibiting the loss of visual acuity associated with AMD, which comprises, administering to a patient a pharmaceutically effective amount from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 2 (original) The method of claim 1, wherein the compound is administered as a juxtascleral depot.

Claim 3 (canceled)

Claim 4 (currently amended) The method of claim ~~3~~2, wherein the depot comprises 15 mg of compound.

Claim 5 (currently amended) A method for maintaining visual acuity in a person suffering from AMD, which comprises administering to a patient a pharmaceutically effective amount from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 6 (original) The method of claim 5, wherein the compound is administered as a juxtascleral depot.

Claim 7 (canceled)

Claim 8 (currently amended) The method of claim ~~7~~6, wherein the depot comprises 15 mg of compound.

Claim 9 (currently amended) A method for the inhibition of lesion growth associated with AMD, which comprises administering to a patient ~~a pharmaceutically effective amount~~from 3 mg – 30 mg of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtascleral injection, juxtascleral implant, intravitreal injection, or implant.

Claim 10 (original) The method of claim 9, wherein the compound is administered as a juxtascleral depot.

Claim 11 (canceled)

Claim 12 (currently amended) The method of claim ~~11~~10, wherein the depot comprises 15 mg of compound.

Claim 13 (previously presented) The method of any one of claims 1, 5, or 9, wherein the compound is administered in a juxtascleral implant.

Claim 14 (currently amended) A method for inhibiting blood vessel growth associated with AMD, said method comprising administering to a patient ~~a pharmaceutically effective amount~~from 3 mg – 30 mg of the compound anecortave acetate or its accompanying alcohol, wherein the administering is by juxtascleral injection, intravitreal injection, juxtascleral implant, or other implant.

Claim 15 (canceled)

Claim 16 (currently amended) The method of claim ~~15~~14, wherein the amount of compound administered is 15 mg.

Serial No.: 10/606,501  
Filed: 26 June 2003  
Page 4

Claim 17 (previously presented)  
predominantly classic subfoveal lesion.

The method of claim 9, wherein the lesion is a

Claim 18 (previously presented)  
minimally classic lesion.

The method of claim 9, wherein the lesion is a